Single User License
INR 100335
Site License
INR 200670
Corporate User License
INR 301005

Service Tax Additional

select a format

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500


Request a quote
Request a Customized research
Request for Sample Report

Recent Viewed Reports

Why Ken Reasearch?


While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"

REGiMMUNE Corporation-Product Pipeline Review-2015

REGiMMUNE Corporation-Product Pipeline Review-2015

  Request for Sample Report

Executive Summary

REGiMMUNE Corporation-Product Pipeline Review-2015


Global Markets Direct's, 'REGiMMUNE Corporation-Product Pipeline Review-2015', provides an overview of the REGiMMUNE Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of REGiMMUNE Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of REGiMMUNE Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of REGiMMUNE Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the REGiMMUNE Corporation's pipeline products

Reasons To Buy

Evaluate REGiMMUNE Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of REGiMMUNE Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the REGiMMUNE Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of REGiMMUNE Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of REGiMMUNE Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of REGiMMUNE Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

REGiMMUNE Corporation Snapshot 5

REGiMMUNE Corporation Overview 5

Key Information 5

Key Facts 5

REGiMMUNE Corporation-Research and Development Overview 6

Key Therapeutic Areas 6

REGiMMUNE Corporation-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

REGiMMUNE Corporation-Pipeline Products Glance 10

REGiMMUNE Corporation-Clinical Stage Pipeline Products 10

Phase II Products/Combination Treatment Modalities 10

REGiMMUNE Corporation-Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

REGiMMUNE Corporation-Drug Profiles 13

RGI-2001 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

RGI-1001 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

RGI-3100 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

RGI-5000 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

RGI-4000 Series 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

REGiMMUNE Corporation-Pipeline Analysis 19

REGiMMUNE Corporation-Pipeline Products by Route of Administration 19

REGiMMUNE Corporation-Pipeline Products by Molecule Type 20

REGiMMUNE Corporation-Recent Pipeline Updates 21

REGiMMUNE Corporation-Dormant Projects 22

REGiMMUNE Corporation-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Appendix 24

Methodology 24

Coverage 24

Secondary Research 24

Primary Research 24

Expert Panel Validation 24

Contact Us 24

Disclaimer 25

List of Tables

REGiMMUNE Corporation, Key Information 5

REGiMMUNE Corporation, Key Facts 5

REGiMMUNE Corporation-Pipeline by Indication, 2015 7

REGiMMUNE Corporation-Pipeline by Stage of Development, 2015 8

REGiMMUNE Corporation-Monotherapy Products in Pipeline, 2015 9

REGiMMUNE Corporation-Phase II, 2015 10

REGiMMUNE Corporation-Preclinical, 2015 11

REGiMMUNE Corporation-Discovery, 2015 12

REGiMMUNE Corporation-Pipeline by Route of Administration, 2015 19

REGiMMUNE Corporation-Pipeline by Molecule Type, 2015 20

REGiMMUNE Corporation-Recent Pipeline Updates, 2015 21

REGiMMUNE Corporation-Dormant Developmental Projects,2015 22

REGiMMUNE Corporation, Other Locations 23

List of Figures

REGiMMUNE Corporation-Pipeline by Top 10 Indication, 2015 7

REGiMMUNE Corporation-Pipeline by Stage of Development, 2015 8

REGiMMUNE Corporation-Monotherapy Products in Pipeline, 2015 9

REGiMMUNE Corporation-Pipeline by Top 10 Molecule Type, 2015 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of REGiMMUNE Corporation; REGiMMUNE Corporation - Key Therapeutics; REGiMMUNE Corporation - Pipeline Overview and Promising Molecules; REGiMMUNE Corporation - News; REGiMMUNE Corporation - Latest Updates; REGiMMUNE Corporation - Pipeline; REGiMMUNE Corporation - Discontinued/Dormant Projects

Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204


Company Brochure

Engage with Us

query [@]